Skip to main content
Advertisement
  • Loading metrics

Development and validation of systems for genetic manipulation of the Old World tick-borne relapsing fever spirochete, Borrelia duttonii

  • Clay D. Jackson-Litteken ,

    Contributed equally to this work with: Clay D. Jackson-Litteken, Wanfeng Guo

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing

    Current address: Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America

    Affiliation Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  • Wanfeng Guo ,

    Contributed equally to this work with: Clay D. Jackson-Litteken, Wanfeng Guo

    Roles Data curation, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review & editing

    Affiliation Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  • Brandon A. Hogland,

    Roles Data curation, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review & editing

    Affiliation Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  • C. Tyler Ratliff,

    Roles Data curation, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review & editing

    Affiliation Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  • LeAnn McFadden,

    Roles Formal analysis, Validation, Visualization, Writing – review & editing

    Affiliation Department of Biology, University of Arkansas at Little Rock, Little Rock, Arkansas, United States of America

  • Marissa S. Fullerton,

    Roles Data curation, Validation, Visualization, Writing – review & editing

    Affiliation Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  • Daniel E. Voth,

    Roles Data curation, Validation, Visualization, Writing – review & editing

    Affiliation Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  • Ryan O. M. Rego,

    Roles Validation, Visualization, Writing – review & editing

    Affiliations Institute of Parasitology, Biology Centre CAS, České Budějovice, Czech Republic, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic

  • Jon S. Blevins

    Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

    jsblevins@uams.edu

    Affiliation Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

Abstract

Relapsing fever (RF), a vector-borne disease caused by Borrelia spp., is characterized by recurring febrile episodes due to repeated bouts of bacteremia. RF spirochetes can be geographically and phylogenetically divided into two distinct groups; Old World RF Borrelia (found in Africa, Asia, and Europe) and New World RF Borrelia (found in the Americas). While RF is a rarely reported disease in the Americas, RF is prevalent in endemic parts of Africa. Despite phylogenetic differences between Old World and New World RF Borrelia and higher incidence of disease associated with Old World RF spirochete infection, genetic manipulation has only been described in New World RF bacteria. Herein, we report the generation of genetic tools for use in the Old World RF spirochete, Borrelia duttonii. We describe methods for transformation and establish shuttle vector- and integration-based approaches for genetic complementation, creating green fluorescent protein (gfp)-expressing B. duttonii strains as a proof of principle. Allelic exchange mutagenesis was also used to inactivate a homolog of the Borrelia burgdorferi p66 gene, which encodes an important virulence factor, in B. duttonii and demonstrate that this mutant was attenuated in a murine model of RF. Finally, the B. duttonii p66 mutant was complemented using shuttle vector- and cis integration-based approaches. As expected, complemented p66 mutant strains were fully infectious, confirming that P66 is required for optimal mammalian infection. The genetic tools and techniques reported herein represent an important advancement in the study of RF Borrelia that allows for future characterization of virulence determinants and colonization factors important for the enzootic cycle of Old World RF spirochetes.

Author summary

Relapsing fever is a globally distributed, vector-borne bacterial infection that is characterized by recurring febrile episodes. The causative Borrelia spp. were identified over 100 years ago, but little is known regarding factors required for mammalian infection or vector colonization/transmission. Relapsing fever Borrelia can be geographically and phylogenetically divided into distinct clades; New World, found in the Americas, and Old World, found in Africa, Europe, and Asia. Although Old World relapsing fever Borrelia represent major causes of disease in endemic regions of the world, genetic studies aimed at identifying bacterial gene products required during the tick-vertebrate infectious cycle have focused on the less commonly reported New World relapsing fever Borrelia. Herein, we begin to address this knowledge gap by developing techniques and molecular tools for genetic manipulation of the Old World tick-borne relapsing fever spirochete, Borrelia duttonii. This genetic system will lay the foundation for future studies aimed at identifying bacterial factors required during the enzootic cycle of B. duttonii.

Introduction

Borrelia spp. are globally distributed, vector-borne bacteria that cause diverse diseases, rendering these pathogens an immense public health concern [1,2]. Borrelia can be divided into two distinct groups, relapsing fever (RF) and Lyme disease (LD) Borrelia, based on associated disease courses, vector/enzootic cycles, and additional phylogenetic differences [13]. Infection with RF spirochetes is characterized by recurring severe, febrile episodes that coincide with repeated bouts of high-level bacteremia (up to 108 bacteria/ml of blood) [1,48]. Furthermore, infection by RF Borrelia can lead to more severe symptoms and outcomes, such as acute respiratory distress syndrome, jaundice, meningitis, splenomegaly, and perinatal mortality [4,9,10]. Alternatively, mammalian infection with LD Borrelia results in lower levels of bacteremia (103−104 bacteria/ml of blood) that is restricted to early stages of infection, after which it disseminates into multiple host tissues [11]. Therefore, symptoms of RF are primarily associated with acute bacteremia, whereas most LD symptoms occur because of chronic tissue colonization (e.g., arthritis, neuroborreliosis, and carditis) [2]. In addition, arthropod vectors differ greatly between RF and LD Borrelia. RF bacteria are transmitted by the human body louse [louse-borne relapsing fever (LBRF)] or Ornithodoros or Ixodes spp. ticks [tick-borne relapsing fever (TBRF)], while LD spirochetes are only transmitted by Ixodes spp. ticks [1217]. The different disease courses resulting from infection by LD and RF Borrelia and their disparate enzootic cycles involving distinct vectors suggest that these two groups of bacteria have likely evolved to encode different factors required for vector acquisition and colonization, transmission, and vertebrate infection. Because most molecular research has focused primarily on LD Borrelia, a significant gap exists in our understanding of the biology of RF spirochetes [18,19].

RF Borrelia can be further subdivided into New World (found in the Americas) and Old World (found in Africa, Asia, and Europe) species [4,5,16,20]. New World RF spirochetes include Borrelia turicatae, which is found in the arid climate of the southwestern United States, and Borrelia hermsii and Borrelia parkeri, the causes of RF in the mountainous regions of the western United States and southwestern Canada [4,5,12,13,2123]. Old World RF spirochetes include Borrelia crocidurae and Borrelia duttonii, which are endemic to western and eastern Africa, respectively, Borrelia persica, a causative agent of TBRF in Eurasia, and Borrelia recurrentis, the LBRF spirochete responsible for epidemic RF in eastern Africa [2430]. RF spirochetes were historically classified into New World and Old World species based solely on geographic separation, but phylogenetic analyses have revealed genomic differences in these bacteria, supporting the separation of the groups into two distinct clades [26,3134].

Although RF is globally distributed, the public health impact varies throughout the world. While RF is a relatively rare and possibly underreported disease in the Americas, this infection is endemic and highly prevalent in parts of Africa [1,4,5,20,2527,32]. In fact, RF has been reported as the most common bacterial infection in Senegal, the most prevalent cause of fever in rural Zaire, and a top 10 cause of death in children under the age of 5 in Tanzania [1,25,27,3537]. Furthermore, cases are often unreported or are misdiagnosed as another disease, such as malaria, in endemic regions of Africa, implying that the actual incidence is higher than previously reported [28,38]. Despite the clear public health threat that Old World RF spirochetes represent, very little is known regarding the molecular pathogenesis of these bacteria.

Use of molecular Koch’s postulates provides the most direct way to determine a causal relationship between a bacterial gene, the protein it encodes, and a requirement during the bacterial lifecycle [39,40]. To apply molecular Koch’s postulates, the gene of interest is inactivated, and the phenotype of the mutant is compared to that of the wild-type parent. Additionally, expression of the gene must be restored in the mutant to assess if the phenotype of interest is reversed. While a limited number of studies have applied genetic manipulation in RF Borrelia to investigate proteins potentially required during the bacteria’s enzootic cycle, these studies have only been conducted with the New World RF spirochetes, B. hermsii and B. turicatae [4150]. Extensive geographic separation and phylogenetic differences between New World and Old World RF spirochetes suggests that these two groups likely evolved distinct regulatory pathways and proteins required for mammalian virulence, as well as vector acquisition, colonization, and transmission. Therefore, there is a significant need to develop molecular techniques for the study of Old World RF Borrelia.

Herein, we aimed to develop a genetic system for use in the Old World TBRF spirochete, B. duttonii. First, we developed shuttle vector- and integration-based constructs and methods for electroporation with B. duttonii, creating green fluorescent protein (gfp)-expressing B. duttonii strains to validate the approach. Allelic exchange mutagenesis was then used to inactivate the gene encoding the B. duttonii homolog of P66, a known virulence factor of the LD spirochete, Borrelia burgdorferi [51,52]. Using a murine model of RF, we demonstrated that the B. duttonii p66 mutant was attenuated. Finally, this p66 mutant was complemented using shuttle vector- and cis integration-based approaches to restore production of P66 and murine infectivity of the p66 mutant strains. The techniques described in this manuscript represent a foundation for the application of molecular tools to study Old World RF Borrelia and will ultimately guide research to better understand these understudied pathogens.

Methods

Ethics statement

Murine infections and immunization protocols were performed in accordance with the Guide for the Care and Use of Laboratory Animals, the Public Health Science Policy on Humane Care and Use of Laboratory Animals, and the Animal Welfare Act, and the protocol used was approved by the University of Arkansas for Medical Sciences (UAMS) Institutional Animal Care and Use Committee (IACUC). UAMS is accredited by the International Association for Assessment and Accreditation of Laboratory Animals Care (AAALAC).

Bacterial strains and culture conditions

Bacterial strains used in this study are listed in Table 1. Escherichia coli strain Top10F’ (Life Technologies, Carlsbad, CA) was used for cloning and plasmid propagation and strain LOBSTR-BL21 (DE3)-RIL (Kerafast, Boston, MA) was used for recombinant protein expression. E. coli was grown in lysogeny broth (LB) medium supplemented with 100 μg/ml ampicillin, 5 μg/ml gentamicin, 100 μg/ml spectinomycin, 50 μg/ml kanamycin, or 30 μg/ml chloramphenicol where appropriate. The infectious Ornithodoros moubata tick isolate, B. duttonii strain 1120K3 (designated BdWT), was used in this study [53]. B. duttonii was cultured in liquid modified Barbour-Stoenner-Kelly (mBSK) medium supplemented with 6 or 12% rabbit serum at a pH of 7.6 at 35°C and 3% CO2 [41,54]. B. duttonii was grown in the presence of 40 μg/ml gentamicin, 100 μg/ml streptomycin, or 150 μg/ml kanamycin when necessary.

Generation of B. duttonii shuttle vectors

Primers used in this study are listed in S1 Table. Plasmid and genomic DNA (gDNA) preparations were performed using the Wizard Plus SV Miniprep DNA Purification System (Promega Corp, Fitchburg, WI), and PCR amplifications for cloning were conducted using high-fidelity PrimeSTAR Max DNA Polymerase (TaKaRa Bio, Mountain View, CA). All plasmids and cloned fragments were Sanger sequenced to confirm no mutations were introduced during cloning. Primers and gene nomenclature are based on the B. duttonii strain Ly sequence from Lescot et al. available on NCBI (GenBank assembly accession: GCA_000019685.1) [58]. Multiple-sequence alignments of B. hermsii and B. duttonii plasmid sequences were generated using MUSCLE in MacVector 18.6.4 (MacVector Inc., Apex, North Carolina).

To make the PflaB-aphI resistance marker for the B. duttonii shuttle vector, the putative promoter region for the flaB gene (bdu_150) was amplified from BdWT gDNA (primers: 5’ BdPflaB and 3’ BdPflaB-SOE), and the aphI open reading frame (ORF) was amplified from pBSV2 (primers: 5’ aphI-SOE/Bd and 3’ UAMS-88 Kan AscI) [59]. The promoter and ORF amplicons were then fused by overlap extension PCR, generating the final PflaB-aphI resistance marker flanked by 5’ BglII and 3’ AscI restriction sites. The PflaB-aphI marker was then TA-cloned into pGEM-T Easy (Promega), and the resulting plasmid intermediate was designated pUAMS359. The PflaB-aphI resistance marker from pUAMS359 was subsequently ligated into the B. burgdorferi shuttle vector, pJD44, replacing the aph[3′]-IIIa gene, and generating the plasmid pUAMS363 [55,59,60]. The E. coli ColE1 origin of replication (ori) was amplified from pJD44, (primers: 5’ pJD44 ColE1 ori and 3’ pJD44 ColE1 ori) flanked by 5’ AscI and 3’ BglII restriction sites and TA-cloned into pGEM-T Easy, designated pUAMS353. The putative ori of the B. duttonii pl41 plasmid was amplified from BdWT gDNA (primers: 5’ Bd pl41 ori BamHI and 3’ Bd pl41 ori AscI) flanked by 5’ BamHI and 3’ AscI restriction sites and TA-cloned into pGEM-T Easy, designated pUAMS364. To generate the final B. duttonii shuttle vector, designated pBdSV, the AscI-flanked multiple cloning site (MCS) and PflaB-aphI cassette from pUAMS363, the AscI/BglII-flanked ColE1 ori from pUAMS353, and the BamHI/AscI-flanked putative B. duttonii pl41 ori from pUAMS364 were ligated together. Another version of the shuttle vector was additionally made in which the MCS and aphI resistance cassette from pUAMS363 were ligated into the shuttle vector in the opposite orientation of that in pBdSV, designated pBdSVCCW.

To make a B. duttonii-adapted gfp cassette, the flaB promoter was amplified from BdWT gDNA (primers: 5’ BdflaB/GFP and 3’ BdflaB/GFP_SOE) and the gfp ORF was amplified from pGreenTIR (primers: 5’ GFPtir ORF and 3’ GFPtir ORF) [56, 57]. The flaB promoter and gfp ORF were then fused by overlap extension PCR, and the resulting product was TA-cloned into pGEM-T Easy, designated pUAMS369. The PflaB-gfp cassette was then excised from pUAMS369 with BamHI and HindIII and ligated into the MCS in pBdSV, generating the shuttle vector pBdSV::gfp.

Generation of the pl165-specific integration construct

To create the pl165 integration construct, 5’ (primers: 5’ F1 pl165 int_v2 and 3’ F1 pl165 int_v2.2) and 3’ (primers: 5’ F2 pl165 int_v2.2 and 3’ F2 pl165 int_v2) regions flanking the integration site (907- and 1096-bp in size, respectively) were first amplified and TA-cloned into pGEM-T Easy. The flanking regions were then ligated together with an AscI restriction site between them in pGEM-T Easy, generating the plasmid pUAMS376. To create the gfp integration construct, pBdgfp, a segment of pBdSV::gfp containing the PflaB-gfp and PflaB-aphI cassettes was excised with AscI and ligated into the AscI site in pUAMS376.

Generation of B. duttonii p66 mutational and complementation constructs

To generate the PflgB-aacC1 gentamicin-resistance marker, the putative promoter region for the flgB gene (bdu_297) was amplified from BdWT gDNA (primers: 5’ BdPflgB-AscI and 3’ BdPflgB-SOE), and the aacC1 ORF was amplified from pUAMS4 (primers: 5’ Gent-SOE/Bd and 3’ Gent-AscI/Bd) [46,47]. The promoter and marker amplicons were fused by overlap extension PCR, generating the PflgB-aacC1 resistance marker flanked by AscI restriction sites. The PflgB-aacC1 marker was subsequently ligated into pGEM-T Easy and designated pUAMS356.

The allelic exchange mutagenesis construct to inactivate the p66 homolog of B. duttonii (e.g., bdu_604) was made by first amplifying upstream (primers: 5’ F1 Bd P66 and 3’ F1 Bd P66_AscI; size: 1098 bp) and downstream (primers: 5’ F2 Bd P66_AscI and 3’ F2 P66_BssHII; size: 1032 bp) regions flanking the mutation site and TA-cloning the respective amplicons into pGEM-T Easy. Flanking regions were then ligated together with the PflgB-aacC1 resistance marker from pUAMS356 between them using the AscI restriction site to yield the final p66 mutational construct, designated pBdΔp66.

To create the BdΔp66 shuttle vector complementation construct, the p66 ORF and 540-bp upstream of the coding region were amplified from BdWT gDNA (primers: 5’ Bd P66 comp BamHI and 3’ Bd P66 comp BamHI), and the resulting amplicon was ligated into the pBdSV MCS at its unique BamHI site. The resulting clone was designated pBdSV::p66. To make the p66 cis integration complementation construct, an aadA resistance marker was first adapted for use in BdWT. To generate the PflaB-aadA streptomycin-resistance marker, a 284-bp region upstream of the flagellin (flaB) gene (bdu_150) was amplified from BdWT gDNA (primers: 5’ BdPflaB-AscI_long and 3’ BdPflaB-aadA SOE), and the aadA ORF was amplified from a derivative of the B. burgdorferi flgBp-aadA-trpLt streptomycin/spectinomycin resistant cassette described by Jackson-Litteken et al. and Drecktrah et al. (primers: 5’ BdPflaB-aadA SOE and 3’ aadA ORF term-AscI) [45,46,61]. The resulting amplicons were fused by overlap extension PCR to generate a PflaB-aadA resistance marker flanked by AscI restriction sites; this PflaB-aadA marker was then ligated into pGEM-T Easy and designated pUAMS521. The genomic regions corresponding to a portion of bdu_602 and all of bdu_603 (primers: 5’ F1 Bd P66 and 3’ F1 Bd P66 cis comp; size: 990 bp) or all of bdu_604/p66 and a portion of bdu_605 (primers: 5’ F2 Bd P66 cis comp and 3’ F2 Bd P66_BssHII; size: 2894 bp) were then amplified and cloned into pGEM-T Easy. The two fragments were ligated together in pGEM-T Easy to introduce an AscI site in the bdu_603 and bdu_604 intergenic region, and the PflaB-aadA marker from pUAMS521 was ligated into this unique AscI site. The resulting p66 cis integration complementation construct was designated pBdp66Cis.

Transformation of B. duttonii and confirmation of transformants

Competent cell preparation and electroporation of B. duttonii were performed via previously described methods for B. hermsii and B. turicatae [41,47]. Briefly, the constructs of interest were electroporated into the appropriate strain. Following a 24-hr recovery period in mBSK medium without selection, transformants were selected using corresponding antibiotic treatment. Once viable spirochetes were observed in the post-transformation recovery cultures, individual clones were then isolated by serial-dilution plating. Transformants were confirmed by PCR, and products were separated by electrophoresis in a 0.8% agarose gel and visualized by ethidium bromide staining. GeneRuler DNA Ladder Mix (ThermoFisher Scientific, Waltham, MA) served as the molecular weight standard.

Clones transformed with shuttle vector (e.g., BdSV, BdSVCCW, and BdSV::gfp) were initially confirmed by plasmid recovery in E. coli, restriction digest, and Sanger sequencing. Additionally, PCR was performed with gDNA from these clones to amplify internal regions of aphI (primers: 5’ aphI diag and 3’ aphI diag), gfp (primers: 5’ GFPtir diag and 3’ GFPtir diag), and flaB (primers: 5’ BdFlaB and 3’ BdFlaB). PCR was also performed to amplify an internal region of pl41 to confirm that the endogenous plasmid was not lost (primers: 5’ pl41 diag and 3’ pl41 diag) in shuttle vector transformants.

Successful integration of gfp into pl165 (e.g., Bdgfp) was confirmed by PCR to amplify internal regions of gfp, aphI, and flaB (see above). PCR was also performed to link a region upstream of the insertion site to the gfp allele (primers: 5’ pl165 IG diag and 3’ GFPtir diag) and a region downstream of the insertion site to the aphI allele (primers: 5’ aphI diag and 3’ pl165 IG diag).

Confirmation of the BdΔp66 mutant was performed by PCR to amplify an internal segment of p66 (primers: 5’ Bd P66 diag and 3’ Bd P66 diag), an internal region of aacC1 (primers: 5′ aacC1 diag and 3′ aacC1 diag), and an internal region of flaB (see above). To confirm the pBdSV::p66-transformed BdΔp66 (e.g., BdΔp66SV comp), clones were initially confirmed by plasmid recovery in E. coli, restriction digest, and Sanger sequencing. Additionally, PCR with gDNA from shuttle vector-complemented clones was performed to amplify internal regions of p66, aacC1, and flaB (see above). To confirm BdΔp66 clones transformed with pBdp66Cis (e.g., BdΔp66Cis comp), PCR with gDNA from transformants was performed to amplify internal regions of p66, aacC1, and flaB (see above), as well as aadA (primers: 5’ aadA diag and 5’ aadA diag).

Imaging of B. duttonii

Imaging of gfp-expressing bacteria was performed as previously described [45]. Briefly, strains of interest were grown to late-exponential phase, centrifuged at ~9,400 x g for 5 min, and resuspended in PBS-MgCl2. This step was repeated one more time, after which bacteria were spotted on a 1% agarose pad and covered with a coverslip [62]. Brightfield and fluorescent images were then captured using an Eclipse Ti2 microscope (Nikon Corporation, Tokyo, Japan) under 60X magnification with oil immersion.

Production of recombinant B. duttonii P66 protein

The coding region for the B. duttonii p66 homolog (BDU_604) was amplified using primers that introduced BamHI and SpeI restriction sites on the 5’ and 3’ ends, respectively (primers: 5’ Bd P66 ORF BamHI and 3’ Bd P66 ORF SpeI). The primers amplified a region of B. duttonii P66 corresponding to amino acids 21–612 of the predicted coding region, which was then ligated into pProEX-HTb (Life Technologies) to generate pUAMS481. To produce recombinant P66 protein, pUAMS481 was transformed in E. coli LOBSTR-BL21(DE3)-RIL. Expression and purification of recombinant P66 were performed as previously described, except all buffers were adjusted to a final pH 9.0 [45]. Final elution samples were buffer exchanged to 1X phosphate buffered saline (PBS), 2M urea, 5% SDS and concentrated with a 50-kDa molecular weight cutoff (MWCO) Amicon Ultra Centrifugal Filter (MilliporeSigma, Burlington, MA). The concentration of purified recombinant P66 was determined with a DC protein assay kit (Bio-Rad Laboratories, Hercules, CA).

Generation of P66-specific antisera

The antigen-adjuvant emulsion was generated by combining 25 μg of recombinant P66 in 200 μL of sterile 1X PBS with an equal volume of AddaVax adjuvant (InvivoGen, San Diego, CA). Three- to four-week-old, female Sprague-Dawley rats (Envigo, Indianapolis, IN) were injected subcutaneously at two sites with 200 μL of emulsion per injection. Rats were boosted twice at four-week intervals with 25 μg of recombinant protein and AddaVax as described above. Rats were euthanized and serum was collected two weeks after the second boost [45].

Murine infections

The murine model of B. duttonii infection was adapted from a previous model used for B. turicatae and B. hermsii [45,46,6365]. BdWT, BdΔp66, BdΔp66SV comp, and BdΔp66Cis comp were grown to mid-log phase, enumerated by dark-field microscopy, and diluted in fresh mBSK media to a concentration of 103 spirochetes/mL. Four- to six-week-old Swiss Webster mice (Charles River Laboratories, Wilmington, MA) were injected intradermally/subcutaneously in the thoracic region with 100 μL of suspension containing a total of 102 bacteria. On days 3–14 post-infection, 2.5 μL blood samples were collected via tail vein nick, combined with 47.5 μL of SideStep Lysis & Stabilization Buffer (Agilent Technologies, Santa Clara, CA), and stored at -80°C until quantitative PCR (qPCR) was performed (see below). 2.5 μL of blood was also added to 1 ml of mBSK medium containing 1X Borrelia antibiotic mixture (BAM) (Monserate, San Diego, CA) to culture bacteria from the blood. On day 14 post-infection, mice were euthanized, and serum was collected for seroconversion analyses (see below). Naïve mice were also sacrificed, and blood was added to lysis/stabilization buffer at a 1:18 ratio for use in qPCR standards (see below). To assess bacterial outgrowth from the blood, blood cultures were analyzed at two-weeks post-collection by dark-field microscopy. 20 fields of view were scanned, and the presence of one or more spirochetes was considered culture positive.

qPCR for bloodstream bacterial burdens

The method for qPCR to quantify bloodstream bacterial burden was adapted from previous experiments with B. turicatae using flaB as a target [45,46,6365]. To generate a qPCR standard, BdWT was cultured to late-exponential growth phase and pelleted by centrifugation at 6,000 x g for 15 min at room temperature. The cells were then resuspended in PBS containing 5 mM MgCl2 (PBS-MgCl2). This wash step was repeated two more times. After the final resuspension in PBS-MgCl2, bacteria were quantified by dark-field microscopy. Tenfold serial dilutions were then made from this resuspension from 104−108 bacteria/ml in PBS-MgCl2, and dilutions were combined with naïve blood in lysis/stabilization buffer at a 1:19 ratio. For use as a no-template control, nuclease-free water was diluted tenfold in PBS-MgCl2 and added to naïve blood in lysis/stabilization buffer at a 1:19 ratio. In a 96-well real-time PCR reaction plate, 17 μL of master mix consisting of 1X SsoAdvanced Universal Probes Supermix (Bio-Rad Laboratories), 400 nM of each primer (Bd FlaB IDT FWD and Bd FlaB IDT REV) and 300 nM of probe (Bd FlaB IDT PRB) was added to each well. 3 μL of murine blood sample in lysis/stabilization buffer or standard preparation were then added in a 20 μL reaction. qPCR reactions for blood samples and standards were performed in triplicate. The QuantStudio 6 Pro Real-Time PCR System (ThermoFisher Scientific) was used for real-time PCR, and reaction conditions included an initial 2 min, 50°C step followed by a 10 min, 95°C hold for polymerase activation. Amplification was then achieved by 40 cycles of DNA denaturation at 95°C for 15 sec and primer annealing/DNA extension at 60°C for 60 sec. Following completion of the qPCR reaction, data was imported into GraphPad Prism version 9 (GraphPad Software, San Diego, CA) for analysis. Mean peak bacterial burdens (first peak at ~8 days and second peak at ~12 days) and the area under the curve (AUC) for each group of mice were compared using the Kruskal-Wallis test. Difference with P values <0.05 were considered statistically significant.

SDS-PAGE and immunoblotting

SDS-PAGE and immunoblot analyses were performed as previously described [45,66]. Briefly, whole lysates containing the equivalent of 2 x 107 bacteria were separated by SDS-PAGE and transferred to nitrocellulose. Membranes were subsequently probed with rat antiserum recognizing P66 (see above), and horseradish peroxidase (HRP)-conjugated goat anti-rat IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) was used as a secondary antibody. To assess equal loading, membranes were additionally probed for FlaB using chicken anti-B. burgdorferi FlaB IgY as the primary antibody and HRP-conjugated donkey anti-chicken IgY (Jackson ImmunoResearch Laboratories) as a secondary antibody [66]. Colorimetric detection of protein was achieved using 4-chloro-1-naphthol as a substrate. To evaluate seroconversion, whole cell lysates were prepared from BdWT bacteria grown to the late exponential growth phase, and volumes containing the equivalent of 2 x 107 cells were separated by SDS-PAGE and transferred to PVDF. Membranes were probed with serum from mice collected at 14 days post-infection (1:1000 dilution), and HRP-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) served as the secondary antibody (1:1000 dilution). Reactivity was detected using SuperSignal West Dura extended duration substrate (ThermoFisher Scientific). For seroconversion immunoblots, all images were manually captured for 3 sec without image optimization. Pooled serum from naïve mice and secondary-only exposed controls were also included for the comparison. Precision Plus Protein All Blue Prestained Protein Standard (Bio-Rad Laboratories) was used for the molecular weight standard.

Results

Development of a shuttle vector for use in B. duttonii

Despite the public health relevance of Old World RF spirochetes, our knowledge regarding the pathogenesis of these bacteria is limited. This is due in part to the lack of techniques to genetically manipulate these pathogens. To begin addressing this gap in the TBRF Borrelia field, we sought to develop the requisite genetic tools for use in the Old World RF spirochete, B. duttonii. First, we aimed to make a shuttle vector that is competent for replication in both E. coli and B. duttonii. To identify a putative B. duttonii ori for the shuttle vector, the plasmid sequences of strain Ly were scanned for regions homologous to the B. hermsii ori used for generation of pBhSV-2 [41]. The cloned origin of replication, derived from B. duttonii pl41, included a portion of bdu_4015, all of bdu_4016 and bdu_4017, and 137 bp upstream of bdu_4017. A kanamycin resistance cassette was generated for B. duttonii by fusing the putative promoter for the flagellin gene (flaB; bdu_150) to the aphI start codon [45,59]. This aphI resistance cassette was then ligated together with the MCS from pJD44, an E. coli ColE1 ori, and the putative ori from B. duttonii pl41, generating the shuttle vector, pBdSV (Fig 1A) [41,55,59,60]. An alignment of the ori regions of B. hermsii strain DAH lp27 and the pl41 analogous region amplified from B. duttonii strain 1120K3 is shown in S1 Fig (67.7% identical). A second version of the shuttle vector was additionally made in which the aphI cassette was oriented in the opposite direction of that in pBdSV, designated pBdSVCCW. To assess if a gene could be successfully expressed from the shuttle vector, a gfp reporter was made by fusing the B. duttonii flaB promoter to a gfp allele and ligating this cassette into the MCS of pBdSV, generating pBdSV::gfp [56,57].

thumbnail
Fig 1. Generation of the B. duttonii shuttle vector.

(A) Diagram illustrating the two B. duttonii shuttle plasmids, pBdSV and pBdSVCCW, developed in this study. In pBdSVCCW, the MCS and aphI resistance cassette from pUAMS363 were ligated in the opposite orientation of this region in pBdSV. (B) Genotypic confirmation of shuttle vector transformants. PCR was performed with BdWT gDNA, the relevant shuttle vectors, and gDNA from B. duttonii electroporated with each of the pBdSV constructs to amplify internal regions of aphI (624 bp), gfp (456 bp), pl41 (326 bp), and flaB (531 bp). PCR was also performed with no template (H2O) as a contamination control. “MW” denotes the DNA standard, and numbers to the left indicate molecular weight in kb.

https://doi.org/10.1371/journal.pntd.0012348.g001

To determine if pBdSV, pBdSVCCW, and pBdSV::gfp were capable of autonomous replication in B. duttonii, the three shuttle vectors were transformed into BdWT, creating the strains, BdSV, BdSVCCW, and BdSV::gfp, respectively. Clones were first confirmed to harbor the shuttle vectors by plasmid recovery in E. coli, followed by restriction digest and sequencing of the respective plasmids. PCR was then performed with gDNA from each clone to amplify internal regions of aphI, gfp, and flaB (Fig 1B). As expected, all B. duttonii transformants were positive for aphI, whereas only BdSV::gfp was positive for gfp. PCR for flaB, which served as an amplification control, resulted in amplicons of the appropriate size in all B. duttonii strains. Next, it was possible that transformation of a pl41-derived shuttle vector into B. duttonii could result in plasmid incompatibility and cause loss of the endogenous pl41 plasmid [48,59,6773]. Therefore, a PCR was performed to amplify an internal region of pl41 that was not part of the ori sequence used for generation of pBdSV. All shuttle vector-containing clones screened positive for the endogenous copy of pl41, demonstrating that pBdSV did not displace pl41 in these B. duttonii transformants (Fig 1B). Finally, to determine that a heterologous gene could be expressed from pBdSV, BdSV::gfp was imaged by fluorescence microscopy (Fig 2). As expected, BdSV::gfp exhibited a bright green fluorescence, but BdWT did not. In all, these results demonstrate successful generation of a shuttle vector capable of autonomous replication in B. duttonii that can be used for genetic complementation and ectopic expression experiments (see below).

thumbnail
Fig 2. Fluorescent imaging of gfp-expressing B. duttonii.

BdWT, BdSV::gfp, and Bdgfp strains were visualized by either brightfield (left) or fluorescence (right) microscopy. Two biological replicate cultures were examined and shown are representative images from one replicate. Scale bar = 10 μm.

https://doi.org/10.1371/journal.pntd.0012348.g002

Development of a trans integration approach for B. duttonii

While the intrinsically higher transformation efficiency of shuttle vectors makes them easy to use for in vitro expression and complementation experiments, shuttle vectors are not always ideal for in vivo applications because the lack of antibiotic selection makes them less stable. Therefore, we sought to develop a trans integration approach for use in B. duttonii that would recombine gene(s) of interest into the genome [18,7476], which could prove more optimal for use in animal infection studies. A site on pl165, which is analogous to the large linear plasmids of New World RF Borrelia, between the genes bdu_1105 and bdu_1106 was chosen as a prospective integration site. This site was selected because it is a large intergenic region (248 bp) between convergently transcribed genes, decreasing the possibility that integration at this site will result in polar mutation effects. To test if a gene could be inserted at this region in pl165, regions flanking the prospective integration site were first amplified, and a segment of pBdSV::gfp containing the aphI and gfp cassettes was excised and ligated between them, creating the integration construct, pBdgfp (Fig 3A). This construct was then transformed into BdWT, generating Bdgfp. Genotypic confirmation of integration in Bdgfp was achieved by PCR to amplify internal regions of gfp and aphI, as well as by a PCR to amplify from upstream of the 5’ flanking region used for the integration construct to a site within the gfp gene and a PCR to amplify from within the aphI gene to a site downstream of the 3’ flanking region used for the integration construct (Fig 3B). As expected, Bdgfp screened positive for gfp and aphI, whereas BdWT did not. Additionally, PCR linking sites on pl165 flanking the segments used for the integration construct to sites within the gfp and aphI ORFs yielded amplicons of the appropriate size in Bdgfp, but failed to generate products when BdWT gDNA or pBdgfp was used as a template. Finally, a PCR for flaB, which served as an amplification control, resulted in products of the appropriate size for BdWT and Bdgfp. Fluorescence microscopy was then used to demonstrate expression of gfp in Bdgfp (Fig 2). As expected, Bdgfp fluoresced green, whereas BdWT exhibited no fluorescence. In all, these results confirm that the integration site selected within pl165 can be used for insertion of genes, validating use of this approach for genetic expression and complementation experiments.

thumbnail
Fig 3. Use of the trans integration approach to generate gfp-expressing B. duttonii.

(A) Generation of Bdgfp. BdWT was transformed with an allelic exchange construct (pBdgfp) to insert PflaB-gfp and PflaB-aphI cassettes into pl165, generating Bdgfp. Primers used for PCR in Fig 3B are denoted with numbered smaller arrows. (B) Genotypic confirmation of Bdgfp. PCR was performed with BdWT gDNA, pBdgfp plasmid, and Bdgfp gDNA to amplify an internal segment of gfp (P1+P2; 456 bp), an internal segment of aphI (P3+P4; 624 bp), a segment spanning regions of bdu_1105 and PflaB-gfp (P5+P2; 1967 bp), a segment spanning regions of PflaB-aphI and bdu_1106 (P3+P6; 1937 bp), and an internal segment of flaB (531 bp). PCR was also performed with no template (H2O) as a contamination control. “MW” denotes DNA standard, and numbers to the left indicate molecular weight in kb.

https://doi.org/10.1371/journal.pntd.0012348.g003

Allelic exchange mutagenesis in B. duttonii

The above data confirmed successful transformation of B. duttonii with the shuttle vector and pl165-targeting integration construct. As future work will aim to characterize bacterial factors required for the B. duttonii enzootic cycle, it was also necessary to develop and confirm methods for allelic exchange mutagenesis in B. duttonii. As a proof of principle, we chose to mutate a homolog of a gene that is known to be required for mammalian infection by the related LD spirochete, B. burgdorferi. Specifically, P66 can function as both an adhesin and a porin in B. burgdorferi, so the gene encoding the B. duttonii P66 homolog (BDU_604) was targeted for allelic exchange mutagenesis [51,52,7785]. BDU_604 and P66 of B. burgdorferi strain B31 are 53.7% identical and their genes are colinear in the chromosome. A gentamicin resistance marker was first adapted for use in B. duttonii by amplifying the putative promoter region for the flagellar basal body rod (flgB) gene and fusing it to the start codon of the aacC1 ORF [41,46,47]. The B. duttonii-adapted aacC1 marker was subsequently ligated between regions flanking bdu_604, replacing a 1750-bp region of the ORF and generating the mutational construct, pBdΔp66. This construct was then electroporated into BdWT, and transformants were selected with gentamicin (Fig 4A).

thumbnail
Fig 4. Mutation and complementation of B. duttonii p66.

(A) Schematic representation of the relevant regions of the chromosomes and relevant constructs used to generate BdΔp66 mutant and BdΔp66Cis comp. BdWT was transformed with an allelic exchange construct, pBdΔp66, to replace an internal region of p66 with PflgB-aacC1 marker, generating BdΔp66. To restore p66 in BdΔp66, the mutant was transformed with pBdp66Cis to replace the PflgB-aacC1 with an intact copy of p66 and PflaB-aadA, generating BdΔp66Cis comp. Numbered arrows represent approximate locations of primers used in panel B. (B) Genotypic confirmation of BdΔp66, BdΔp66SV comp, and BdΔp66Cis comp. PCR was performed with gDNAs isolated from BdWT, BdΔp66, BdΔp66SV comp, and BdΔp66Cis comp. Plasmids pBdΔp66, pBdSV::p66, and pBdp66Cis were included as positive amplification controls, and PCR was also performed with no template (H2O) as a purity control. Diagnostic PCR, identified on right, was designed to amplify internal regions of p66 (P1+P2; 565 bp), aacC1 (P3+P4; 489 bp), aadA (P5+P6; 463 bp), or flaB (531 bp). “MW” denotes the DNA standard, and numbers to the left indicate molecular weight in kb. (C) Immunoblot confirmation of BdΔp66, BdΔp66SV comp, and BdΔp66Cis comp. Whole-cell lysates, prepared from bacteria in late-exponential phase cultures, were separated by SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were then probed with antiserum or antibody against P66 or FlaB, respectively. Antiserum/antibodies used to detect the respective proteins are indicated to the right. “MW” denotes the protein standard, and numbers to the left indicate molecular weight in kDa.

https://doi.org/10.1371/journal.pntd.0012348.g004

A B. duttonii p66 mutant clone, designated BdΔp66, was confirmed by PCR with primer pairs that amplified a region within the deleted portion of the p66 ORF or an internal region of aacC1 (Fig 4B). An internal region of flaB was also amplified as a positive control. As expected, PCR for the internal region of bdu_604 resulted in an amplicon of the appropriate size for BdWT, while no amplicon was observed for BdΔp66. Alternatively, BdΔp66 screened positive for the aacC1 marker, while BdWT did not. Additionally, PCR for a region flanking the site of mutation resulted in products of the appropriate size for BdWT and BdΔp66. Finally, PCR for an internal region of flaB resulted in amplicons for both BdWT and BdΔp66 strains (Fig 4B).

Genetic complementation was used to restore expression of p66 in BdΔp66. There are three commonly used methods for genetic complementation; i) complementation in cis by replacing the mutated gene with a wild-type allele, ii) complementation in trans by transforming a plasmid that harbors a wild-type copy of the gene into the mutant strain, and iii) complementation in trans by inserting a wild-type copy of the gene into a stable genomic element (e.g., endogenous plasmid or chromosome) in the mutant strain [19]. We encountered complications cloning the p66 region into the pl165-targeting trans integration construct (e.g., pUAMS376), so cis complementation and shuttle-vector-based trans complementation were pursued in this study. To generate the p66 shuttle vector complementation construct, the p66 ORF and 540-bp upstream of the coding region were amplified from BdWT and cloned into pBdSV to generate pBdSV::p66. For the cis integration p66 complementation construct, an aadA resistance marker was first adapted for B. duttonii by fusing the promoter region of BdWT flaB to the aadA ORF to generate PflaB-aadA [41,46,61,86]. The genomic regions flanking bdu_604/p66, corresponding to a portion of bdu_602 with all of bdu_603 and all of bdu_604 with a portion of bdu_605 were then amplified, and the PflaB-aadA marker was then ligated into a unique AscI site introduced downstream of the p66 ORF. The resulting p66 cis complementation construct was designated pBdp66Cis (Fig 4A). pBdSV::p66 and pBdp66Cis were electroporated into BdΔp66, and transformants were designated BdΔp66SV comp and BdΔp66Cis comp, respectively. BdΔp66SV comp and BdΔp66Cis comp were initially confirmed by PCR, and p66 was detected in both complemented strains (Fig 4B). In BdΔp66Cis comp, the aadA marker was detected instead of aacC1, whereas aacC1 was detected in BdΔp66SV comp. The pBdSV::p66 shuttle vector was also recovered from BdΔp66SV comp and confirmed by restriction digestion and sequencing. Finally, loss of P66 production in BdΔp66 and restoration of P66 in BdΔp66SV comp and BdΔp66Cis comp was confirmed by immunoblot (Fig 4C). In all, these results indicate the first successful mutagenesis of a gene in an Old World RF spirochete and confirm that allelic exchange is a viable option for targeted mutagenesis in B. duttonii.

The BdΔp66 mutant is attenuated in a murine model of RF

Murine infection models are commonly used to determine if RF spirochete mutants are competent for mammalian infection, [4150,65]. We therefore adapted the previously described murine infection model for the New World RF Borrelia, B. turicatae, for use with B. duttonii [4447,50]. Groups of four mice were intradermally/subcutaneously inoculated with 102 spirochetes of BdWT, BdΔp66, BdΔp66SV comp, and BdΔp66Cis comp. Blood samples were collected on days 3–14 and analyzed by qPCR to quantify the bacterial number in the bloodstream. Mice infected with BdWT experienced two recurring bouts of high bacteremia with peaks of ~108 bacteria/ml of blood (Fig 5A). In contrast, two mice infected with BdΔp66 failed to reach detectable levels of bacteremia on any day post-infection. The other two BdΔp66-infected mice showed two bacteremia peaks, but the bacteria reached levels lower than BdWT (Fig 5B). In these latter two mice, the first bacteremic peaks reached 105−106 bacteria/ml and ~106 bacteria/ml were detected during the second peak. Statistical analyses comparing the mean peak bacterial burdens or AUC values between BdWT- and BdΔp66-infected mice confirmed statistically significant differences (S2 Fig). To fulfill molecular Koch’s postulates and confirm the requirement for P66 during B. duttonii mammalian infection, genetic complementation was used to restore expression of p66 in BdΔp66 and determine if the infection defect could be reversed. For the genetically complemented strains, bacterial burdens were comparable to BdWT in three of the four mice infected with BdΔp66SV comp (Fig 5C) and in all four mice infected with BdΔp66Cis comp (Fig 5D). Statistical comparison of the data from the BdΔp66Cis comp- and BdΔp66-infected mice confirmed significant differences only in the mean peak bacterial burdens. Neither the AUC values or peak burdens between the BdΔp66SV comp- and BdΔp66-infected groups were statistically significant (S2 Fig). Daily blood samples were also collected and inoculated into mBSK medium to culture B. duttonii from the bloodstream. This approach is predicted to be more sensitive with an estimated limit of infection (LOD) of ~4 x 102 live bacteria/ml [45,46]. BdWT was cultured from the blood of infected mice on multiple days post-infection, but BdΔp66 spirochetes could only be cultured from the two mice that showed the bacteremia peaks. Furthermore, all the mice infected with BdΔp66SV comp and BdΔp66Cis comp were culture positive on at least one day during infection. Seroconversion results agreed with the qPCR results (S3 Fig). Specifically, the two BdΔp66-infected and one BdΔp66SV comp-infected mice that didn’t show detectable levels of bacteremia after infection also did not produce antibodies that reacted against BdWT lysates. Taken together, these results support the notion that P66 is required for optimal mammalian infection and demonstrate our ability to adapt our murine model of RF used for the New World RF bacterium, B. turicatae, to study pathogenesis of the Old World RF spirochete, B. duttonii.

thumbnail
Fig 5. Murine infection phenotype of the B. duttonii p66 mutant and complemented clones.

Groups of four mice were intradermally inoculated with 102 (A) BdWT, (B) BdΔp66, (C) BdΔp66SV comp, and (D) BdΔp66Cis comp spirochetes. On days 3–14 post-infection, bacterial levels in the bloodstream of each mouse were quantified by qPCR. The dashed line indicates the LOD for this assay (104 spirochetes/ml). Daily blood samples were also collected and inoculated into mBSK to culture B. duttonii from the bloodstream. Cultures were analyzed up to two-weeks post-collection by dark-field microscopy and results for each day are indicated below the X-axis; +, positive for spirochetes and -, no spirochetes observed. Numbers above the graphs indicate individual mice in each experimental group, and error bars represent standard error of the mean (SEM).

https://doi.org/10.1371/journal.pntd.0012348.g005

Discussion

Due to the phylogenetic divergence of Old World and New World RF spirochetes, studying representatives from each of these distinct groups of Borrelia could reveal differences in factors required during their respective enzootic cycles [16,26,31,32,34,87,88]. However, to date, genetic manipulation of RF spirochetes has only been described in New World RF Borrelia [4150,65]. To address this gap in the literature, we sought to develop the requisite genetic tools and techniques to study the Old World RF bacterium, B. duttonii. Allelic exchange mutagenesis is the most common method for mutation in Borrelia spp. and was therefore used to attempt inactivation of a B. duttonii gene [18,19,41,47,74,75]. To test this approach, the gene encoding the homolog of the known B. burgdorferi virulence factor, P66, was targeted for inactivation. P66 in LD Borrelia functions as both a porin and an integrin binding adhesin that facilitates transendothelial migration and promotes B. burgdorferi dissemination [51,52,7785], thus we hypothesized that a B. duttonii p66 mutant would not be fully infectious. PCR and immunoblot analyses confirmed successful mutation of p66, and the BdΔp66 mutant was found to be attenuated in a murine model of RF. Importantly, genetic complementation was used to restore P66 production by BdΔp66, which also restored normal infectivity to the mutant and confirmed P66 contributes to mammalian infection by B. duttonii. This manuscript is the first to establish an essential role for a P66 homolog during mammalian infection by any RF spirochete. Little is known about the in vivo function(s) of P66 in RF Borrelia, but Bárcena-Uribarri et al. demonstrated that P66 homologs in three LD spirochetes (B. burgdorferi, Borrelia afzelii, and Borrelia garinii) and three RF species [B. duttonii (Old World), B. recurrentis (Old World), and B. hermsii (New World)] have highly conserved amino acid domains and similar porin biophysical properties in vitro, suggesting that P66 homologs play similar roles across Borrelia species [83]. Future studies will be required to assess the possible function of RF Borrelia P66 homologs in integrin binding and to assess whether potential roles in integrin binding and channel formation are essential during the enzootic cycle.

Two methods were used to genetically complement the BdΔp66 mutant in this study. For the first method, a B. duttonii shuttle vector was generated and p66 along with its putative promoter region was inserted into the engineered MCS. While several shuttle vectors have been made for use in the LD spirochetes, few exist for use in RF spirochetes [18,19,41,45,47,7476,89,90]. In fact, prior to this study, shuttle vectors had only been generated for the New World RF spirochetes, B. hermsii and B. turicatae [41,45]. Borrelial shuttle vectors are generally useful for in vitro experiments, but these plasmids have varying stability in vivo in the absence of antibiotic selection. In fact, genetic complementation of BdΔp66 using pBdSV::p66 resulted in one mouse that did not seroconvert or produce measurable bacteremia in the blood, despite having a positive blood culture on day 10, potentially suggesting loss of the shuttle vector from the population infecting this mouse. As expected, genetic complementation of BdΔp66 using a cis integration approach resulted in full restoration of mammalian infection in all infected mice, validating the use of this approach for future in vivo complementation experiments using our murine model of RF.

In addition to being valuable for use in genetic complementation, the shuttle vector and trans integration methods described herein have potential for other future uses, including heterologous expression experiments. This is evidenced by our ability to express a gfp allele using both approaches in vitro. Expression of gfp has also been used in other Borrelia to study pathogen-host interactions, and Borrelia-tick interactions have been visualized using both B. burgdorferi and B. turicatae strains expressing gfp [50,9193]. Recently, we have developed an Ornithodoros moubata-mouse model of transmission/infection to study tick acquisition, colonization, and transmission [94]. Use of the gfp-expressing Bdgfp reported herein should allow visualization of B. duttonii-tick interactions. Given the evolutionary divergence of Old World and New World RF spirochetes, these studies could reveal differences in the vector phase of the enzootic cycle. While use of gfp-expressing strains to study B. duttonii-host interactions should provide valuable information, this represents just one of many possible applications of our shuttle vector and integration strategies for introduction and ectopic expression of genes in B. duttonii [18,19].

This study lays the foundation for the application of genetic tools to study Old World RF spirochetes, but more work is required to advance the available armamentarium of genetic tools. We successfully adapted three commonly used antibiotic resistance markers in Borrelia for use in B. duttonii; the Pseudomonas aeruginosa Tn1696-derived aacC1 gentamicin marker, the E. coli Tn903-derived aphI kanamycin marker, and the Shigella flexneri plasmid R100-derived aadA streptomycin resistance marker, [41,86,95,96] Future work may require the development of additional resistance markers. Therefore, we plan to expand this available repertoire of B. duttonii markers by adapting commonly used resistance markers in other Borrelia systems, including the Aspergillus terreus-derived blasticidin resistance marker, bsd, and the E. coli-derived hygromycin marker, hph [97,98]. Additionally, while we proposed the potential use of gfp as a reporter gene to visualize B. duttonii in a given environment (e.g., tick tissues), other reporter genes have been adapted for use in Borrelia spp. for similar purposes, as well as to monitor gene expression or track cellular localization of various proteins [18,19,92]. These reporters include chloramphenicol acetyl transferase (CAT), β-galactosidase (LacZ), firefly luciferase, yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), red fluorescent protein (RFP), and orange fluorescent protein (dTomato) [89,91,93,98105]. Future work will also involve adaptation of the genes encoding these other reporters for use in B. duttonii. Finally, development of an inducible expression system would provide the ability to overexpress a gene and determine phenotypes associated with altered expression in vitro or in vivo. We developed one of the first inducible expression systems available for use in B. burgdorferi and have recently adapted this system for use in the New World RF spirochete, B. turicatae [45,99]. Given our prior success, we envision successful adaptation of this system for use in B. duttonii as well.

One significant obstacle to genetic manipulation of Borrelia spp. is the low transformation efficiency relative to other bacterial systems [18,19,41,47,74,75]. With B. duttonii, we have also observed low transformation frequencies, with ~20% of transformations being successful. Therefore, future work will aim at increasing transformation efficiency. Possible changes to test include altering bacterial density/growth phase at the time of harvest, changing the amounts and types of washes performed during electrocompetent cell preparation, and linearization of suicide constructs prior to electroporation. One possible reason for low transformation efficiency observed in B. duttonii though could be the presence of restriction modification systems, which is observed in B. burgdorferi [106109]. Interestingly, mutation of at least one New World RF spirochete restriction modification gene does not impact infectivity [49]. Therefore, it may be possible to generate a strain in which all restriction modification systems have been inactivated that is fully infectious. This strain could then serve as the “wild-type” parent to generate mutants to assess the requirement for certain factors throughout the enzootic cycle. The development of additional resistance markers would be critical to use this strategy however (see above). As an alternative, in vitro methylation could be performed on constructs to transform into B. duttonii, as has been done to increase transformation efficiency in B. burgdorferi [108]. Finally, alternative means of transformation could be explored to assess differences in efficiency relative to electroporation. To date, only one other means of transformation has been explored in a Borrelia species, transformation and storage solution (TSS) transformation [110,111]. While this procedure is not commonly used, it has worked successfully in B. burgdorferi, and, therefore, may serve as a viable alternative to electroporation. Changes in transformation protocols, methods to circumvent B. duttonii restriction-modification systems, and alternative means of transformation will all be the subject of future work.

Herein, we developed the first genetic tools and techniques to begin studying factors required for the enzootic cycle of an Old World RF spirochete using the bacterium, B. duttonii. In all, this study lays the groundwork to begin expanding our knowledge regarding the enzootic cycle and pathogenesis of Old World RF spirochetes. An increased understanding of these neglected, public health-relevant pathogens could ultimately provide better options for prevention and treatment of RF in developing countries where these spirochetes are among the leading causes of bacterial illnesses.

Supporting information

S1 Fig. Alignment of B. hermsii lp27 and the analogous pl41 ori region amplified from B. duttonii.

Shaded boxes indicate nucleotide identity. “Bh” and “Bd” denote B. hermsii strain DAH and B. duttonii strain 1120K3 sequences, respectively.

https://doi.org/10.1371/journal.pntd.0012348.s002

(PDF)

S2 Fig. Statistical analysis of murine infection data.

Mean peak bacterial burdens (first peak at ~8 days and second peak at ~12 days) and the area under the curve (AUC) for each group of mice were compared using the Kruskal-Wallis test. Values are graphed as the geometric means with geometric standard deviations. ns, not significant; *, P < 0.05; and **, P < 0.005.

https://doi.org/10.1371/journal.pntd.0012348.s003

(PDF)

S3 Fig. Seroconversion in mice infected with B. duttonii p66 mutant and complemented clones.

Whole cell lysates of BdWT bacteria were separated by SDS-PAGE, transferred to PVDF membranes, and probed with serum from mice collected at 14 days post-infection. Images were manually captured for the same length of time. A pooled naïve mouse sample and secondary-only exposed controls were also included in the analysis; e.g., “Naïve” and “2° only”, respectively. “MW” denotes the protein standard, and numbers to the left indicate molecular weight in kDa.

https://doi.org/10.1371/journal.pntd.0012348.s004

(PDF)

Acknowledgments

The authors thank Jennifer Johnson in the UAMS DNA and Next-Generation Sequencing Core facility for technical assistance. We also acknowledge Chris Johnsten for his invaluable expertise and guidance throughout this project.

References

  1. 1. Cutler SJ. Relapsing fever—a forgotten disease revealed. J Appl Microbiol. 2010;108(4):1115–22. Epub 2009/11/06. pmid:19886891.
  2. 2. Steere AC, Strle F, Wormser GP, Hu LDT, Branda JA, Hovius JR, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2. ARTN 16090 WOS:000397870500001. pmid:27976670
  3. 3. Adeolu M, Gupta RS. A phylogenomic and molecular marker based proposal for the division of the genus Borrelia into two genera: the emended genus Borrelia containing only the members of the relapsing fever Borrelia, and the genus Borreliella gen. nov containing the members of the Lyme disease Borrelia (Borrelia burgdorferi sensu lato complex). Anton Leeuw Int J G. 2014;105(6):1049–72. WOS:000336026200006. pmid:24744012
  4. 4. Dworkin MS, Anderson DE Jr., Schwan TG, Shoemaker PC, Banerjee SN, Kassen BO, et al. Tick-borne relapsing fever in the northwestern United States and southwestern Canada. Clin Infect Dis. 1998;26(1):122–31. Epub 1998/02/10. pmid:9455520.
  5. 5. Dworkin MS, Schwan TG, Anderson DE Jr., Borchardt SM. Tick-borne relapsing fever. Infect Dis Clin North Am. 2008;22(3):449–68, viii. Epub 2008/08/30. pmid:18755384.
  6. 6. Stoenner HG, Dodd T, Larsen C. Antigenic variation of Borrelia hermsii. J Exp Med. 1982;156(5):1297–311. Epub 1982/11/01. pmid:7130900; PubMed Central PMCID: PMC2186838.
  7. 7. Cadavid D, Thomas DD, Crawley R, Barbour AG. Variability of a bacterial surface protein and disease expression in a possible mouse model of systemic Lyme borreliosis. J Exp Med. 1994;179(2):631–42. Epub 1994/02/01. pmid:8294872; PubMed Central PMCID: PMC2191368.
  8. 8. Pennington PM, Allred CD, West CS, Alvarez R, Barbour AG. Arthritis severity and spirochete burden are determined by serotype in the Borrelia turicatae-mouse model of Lyme disease. Infect Immun. 1997;65(1):285–92. Epub 1997/01/01. pmid:8975925; PubMed Central PMCID: PMC174589.
  9. 9. Jongen VHWM, vanRoosmalen J, Tiems J, VanHolten J, Wetsteyn JCFM. Tick-borne relapsing fever and pregnancy outcome in rural Tanzania. Acta Obstet Gynecol Scand. 1997;76(9):834–8. WOS:A1997YA56800005. pmid:9351408
  10. 10. Murphy FK, Parker S, Stokich D, Murray M, Fogelman V, Todd R, et al. Acute respiratory distress syndrome in persons with tickborne relapsing fever—Three states, 2004–2005 (Reprinted from MMWR, vol 56, pg 1073–1076, 2007). Jama-J Am Med Assoc. 2007;298(23):2734–6. WOS:000251716000010.
  11. 11. Wang GQ, Ojaimi C, Wu HY, Saksenberg V, Iyer R, Liveris D, et al. Disease severity in a murine model of Lyme borreliosis is associated with the genotype of the infecting Borrelia burgdorferi sensu stricto strain. Journal of Infectious Diseases. 2002;186(6):782–91. WOS:000177694800008. pmid:12198612
  12. 12. Davis GE. Ornithodoros turicata: the possible vector of relapsing fever in southwestern Kansas. Pub Health Rep. 1936;51:1719.
  13. 13. Davis GE. Ornithodoros hermsi and relapsing fever in Oregon. Pub Health Rep. 1941;56:2010–2.
  14. 14. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. Lyme disease-a tick-borne spirochetosis? Science. 1982;216(4552):1317–9. Epub 1982/06/18. pmid:7043737.
  15. 15. Barbour AG. Borreliaceae. In: Whitman WB, Rainey F, Kämpfer P, Truijillo J, Chun J, DeVos P, et al., editors. Bergey’s Manual of Systematics of Archaea and Bacteria: John Wiley & Sons, Inc.; 2018.
  16. 16. Barbour AG, Schwan TG. Borrelia. In: Whitman WB, Rainey F, Kämpfer P, Truijillo J, Chun J, DeVos P, et al., editors. Bergey’s Manual of Systematics of Archaea and Bacteria: John Wiley & Sons, Inc.; 2019.
  17. 17. Fukunaga M, Takahashi Y, Tsuruta Y, Matsushita O, Ralph D, Mcclelland M, et al. Genetic and Phenotypic Analysis of Borrelia-Miyamotoi Sp-Nov, Isolated from the Ixodid Tick Ixodes-Persulcatus, the Vector for Lyme-Disease in Japan. Int J Syst Bacteriol. 1995;45(4):804–10. WOS:A1995RZ21600027. pmid:7547303
  18. 18. Drecktrah D, Samuels DS. Genetic manipulation of Borrelia spp. Curr Top Microbiol Immunol. 2018;415:113–40. Epub 2017/09/18. pmid:28918538; PubMed Central PMCID: PMC5857249.
  19. 19. Rosa PA, Jewett MW. Genetic Manipulation of Borrelia. Curr Issues Mol Biol. 2021;42:307–32. WOS:000600423600008. pmid:33300496
  20. 20. Talagrand-Reboul E, Boyer PH, Bergstrom S, Vial L, Boulanger N. Relapsing Fevers: Neglected Tick-Borne Diseases. Front Cell Infect Microbiol. 2018;8:98. Epub 2018/04/20. pmid:29670860; PubMed Central PMCID: PMC5893795.
  21. 21. Goubau PF. Relapsing fevers. A review. Ann Soc Belg Med Trop. 1984;64(4):335–64. Epub 1984/01/01. pmid:6397148.
  22. 22. Rawlings JA. An overview of tick-borne relapsing fever with emphasis on outbreaks in Texas. Tex Med. 1995;91(5):56–9. Epub 1995/05/01. pmid:7778052.
  23. 23. Lopez JE, Krishnavajhala A, Garcia MN, Bermudez S. Tick-Borne Relapsing Fever Spirochetes in the Americas (vol 3, 16, 2016). Veterinary Sciences. 2019;6(4). ARTN 98 WOS:000565914100024. pmid:31817297
  24. 24. Assous MV, Wilamowski A. Relapsing fever borreliosis in Eurasia—forgotten, but certainly not gone! Clin Microbiol Infect. 2009;15(5):407–14. Epub 2009/06/06. pmid:19489923.
  25. 25. Vial L, Diatta G, Tall A, Ba el H, Bouganali H, Durand P, et al. Incidence of tick-borne relapsing fever in west Africa: longitudinal study. Lancet. 2006;368(9529):37–43. Epub 2006/07/04. pmid:16815378.
  26. 26. Cutler SJ, Abdissa A, Trape JF. New concepts for the old challenge of African relapsing fever borreliosis. Clin Microbiol Infect. 2009;15(5):400–6. Epub 2009/06/06. pmid:19489922.
  27. 27. Dupont HT, La Scola B, Williams R, Raoult D. A focus of tick-borne relapsing fever in southern Zaire. Clin Infect Dis. 1997;25(1):139–44. Epub 1997/07/01. pmid:9243047.
  28. 28. Schwan TG, Anderson JM, Lopez JE, Fischer RJ, Raffel SJ, McCoy BN, et al. Endemic Foci of the Tick-Borne Relapsing Fever Spirochete Borrelia crocidurae in Mali, West Africa, and the Potential for Human Infection. PLoS Negl Trop Dis. 2012;6(11):e1924. Epub 2012/12/05. pmid:23209863; PubMed Central PMCID: PMC3510061.
  29. 29. Naddaf SR, Ghazinezhad B, Sedaghat MM, Asl HM, Cutler SJ. Tickborne Relapsing Fever in Southern Iran, 2011–2013. Emerg Infect Dis. 2015;21(6):1078–80. WOS:000355386900032. pmid:25988268
  30. 30. Kahlig P, Paris DH, Neumayr A. Louse-borne relapsing fever-A systematic review and analysis of the literature: Part 1-Epidemiology and diagnostic aspects. PLoS Negl Trop Dis. 2021;15(3):e0008564. Epub 20210311. pmid:33705384; PubMed Central PMCID: PMC7951878.
  31. 31. Toledo A, Anda P, Escudero R, Larsson C, Bergstrom S, Benach JL. Phylogenetic analysis of a virulent Borrelia species isolated from patients with relapsing fever. J Clin Microbiol. 2010;48(7):2484–9. Epub 2010/05/14. pmid:20463158; PubMed Central PMCID: PMC2897527.
  32. 32. Cutler SJ. Relapsing Fever Borreliae A Global Review. Clin Lab Med. 2015;35(4):847-+. WOS:000366882100009. pmid:26593261
  33. 33. Davis GE. The Relapsing Fevers—Tick-Spirochete Specificity Studies. Exp Parasitol. 1952;1(4):406–10. WOS:A1952YB47400009.
  34. 34. Elbir H, Abi-Rached L, Pontarotti P, Yoosuf N, Drancourt M. African relapsing Fever borreliae genomospecies revealed by comparative genomics. Front Public Health. 2014;2:43. Epub 2014/09/18. pmid:25229054; PubMed Central PMCID: PMC4157404.
  35. 35. Brahim H, Perrier-Gros-Claude JD, Postic D, Baranton G, Jambou R. Identifying relapsing fever Borrelia, Senegal. Emerg Infect Dis. 2005;11(3):474–5. WOS:000227421400023. pmid:15757570
  36. 36. Ndiaye EHI, Diouf FS, Ndiaye M, Bassene H, Raoult D, Sokhna C, et al. Tick-borne relapsing fever Borreliosis, a major public health problem overlooked in Senegal. PLoS Negl Trop Dis. 2021;15(4):e0009184. Epub 20210422. pmid:33886571; PubMed Central PMCID: PMC8096072.
  37. 37. Parola P, Diatta G, Socolovschi C, Mediannikov O, Tall A, Bassene H, et al. Tick-borne relapsing fever borreliosis, rural senegal. Emerg Infect Dis. 2011;17(5):883–5. Epub 2011/05/03. pmid:21529402; PubMed Central PMCID: PMC3321757.
  38. 38. Nordstrand A, Bunikis I, Larsson C, Tsogbe K, Schwan TG, Nilsson M, et al. Tickborne relapsing fever diagnosis obscured by malaria, Togo. Emerg Infect Dis. 2007;13(1):117–23. Epub 2007/03/21. pmid:17370524; PubMed Central PMCID: PMC2725822.
  39. 39. Falkow S. Molecular Koch’s postulates applied to microbial pathogenicity. Rev Infect Dis. 1988;10 Suppl 2:S274-6. Epub 1988/07/01. pmid:3055197.
  40. 40. Falkow S. Molecular Koch’s postulates applied to bacterial pathogenicity—a personal recollection 15 years later. Nat Rev Microbiol. 2004;2(1):67–72. Epub 2004/03/24. pmid:15035010.
  41. 41. Battisti JM, Raffel SJ, Schwan TG. A system for site-specific genetic manipulation of the relapsing fever spirochete Borrelia hermsii. Methods Mol Biol. 2008;431:69–84. Epub 2008/02/22. pmid:18287748.
  42. 42. Fine LM, Earnhart CG, Marconi RT. Genetic transformation of the relapsing fever spirochete Borrelia hermsii: stable integration and expression of green fluorescent protein from linear plasmid 200. J Bacteriol. 2011;193(13):3241–5. Epub 2011/05/10. pmid:21551306; PubMed Central PMCID: PMC3133285.
  43. 43. Fine LM, Miller DP, Mallory KL, Tegels BK, Earnhart CG, Marconi RT. The Borrelia hermsii factor H binding protein FhbA is not required for infectivity in mice or for resistance to human complement in vitro. Infect Immun. 2014;82(8):3324–32. pmid:24866803; PubMed Central PMCID: PMC4136202.
  44. 44. Jackson-Litteken CD, Curtis MW, Armstrong BA, Krishnavajhala A, Filatov S, Blevins JS, et al. Characterization of the arthropod associated lipoprotein (Alp) in the tick-mammalian transmission cycle of Borrelia turicatae. Ticks Tick Borne Dis. 2022;13(6). ARTN 102052 WOS:000883685000002. pmid:36223678
  45. 45. Jackson-Litteken CD, Ratliff CT, Kneubehl AR, Siletti C, Pack L, Lan R, et al. The Diadenylate Cyclase CdaA Is Critical for Borrelia turicatae Virulence and Physiology. Infect Immun. 2021;89(6). ARTN e00787-20 WOS:000652408200012. pmid:33846120
  46. 46. Jackson-Litteken CD, Zalud AK, Ratliff CT, Latham JI, Bourret TJ, Lopez JE, et al. Assessing the contribution of an HtrA family serine protease during Borrelia turicatae mammalian infection. Front Cell Infect Microbiol. 2019;9:290. Epub 2019/08/29. pmid:31456953; PubMed Central PMCID: PMC6700303.
  47. 47. Lopez JE, Wilder HK, Hargrove R, Brooks CP, Peterson KE, Beare PA, et al. Development of genetic system to inactivate a Borrelia turicatae surface protein selectively produced within the salivary glands of the arthropod vector. PLoS Negl Trop Dis. 2013;7(10):e2514. Epub 2013/11/10. pmid:24205425; PubMed Central PMCID: PMC3814808.
  48. 48. Raffel SJ, Battisti JM, Fischer RJ, Schwan TG. Inactivation of genes for antigenic variation in the relapsing fever spirochete Borrelia hermsii reduces infectivity in mice and transmission by ticks. PLoS Pathog. 2014;10(4):e1004056. pmid:24699793; PubMed Central PMCID: PMC3974855.
  49. 49. James AE, Rogovskyy AS, Crowley MA, Bankhead T. Characterization of a DNA adenine methyltransferase gene of Borrelia hermsii and its dispensability for murine infection and persistence. PLoS One. 2016;11(5):e0155798. Epub 2016/05/20. pmid:27195796; PubMed Central PMCID: PMC4873019.
  50. 50. Krishnavajhala A, Wilder HK, Boyle WK, Damania A, Thornton JA, Perez de Leon AA, et al. Imaging of Borrelia turicatae producing the green fluorescent protein reveals persistent colonization of the Ornithodoros turicata midgut and salivary glands from nymphal acquisition through transmission. Appl Environ Microbiol. 2017;83(5):e02503–16. Epub 2016/12/18. pmid:27986725; PubMed Central PMCID: PMC5311397.
  51. 51. Ristow LC, Bonde M, Lin YP, Sato H, Curtis M, Wesley E, et al. Integrin binding by Borrelia burgdorferi P66 facilitates dissemination but is not required for infectivity. Cell Microbiol. 2015;17(7):1021–36. Epub 2015/01/22. pmid:25604835; PubMed Central PMCID: PMC4478124.
  52. 52. Ristow LC, Miller HE, Padmore LJ, Chettri R, Salzman N, Caimano MJ, et al. The beta 3-integrin ligand of Borrelia burgdorferi is critical for infection of mice but not ticks. Mol Microbiol. 2012;85(6):1105–18. WOS:000308584400008. pmid:22758390
  53. 53. Thein M, Bunikis I, Denker K, Larsson C, Cutler S, Drancourt M, et al. Oms38 Is the first identified pore-forming protein in the outer membrane of relapsing fever spirochetes. J Bacteriol. 2008; 190(21):7053–42. Epub 2008/08/29. pmid:18757545; PubMed Central PMCID: PMC2580676.
  54. 54. Barbour AG. Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med. 1984;57(4):521–5. Epub 1984/07/01. pmid:6393604; PubMed Central PMCID: PMC2589996.
  55. 55. Revel AT, Blevins JS, Almazan C, Neil L, Kocan KM, de la Fuente J, et al. bptA (bbe16) is essential for the persistence of the Lyme disease spirochete, Borrelia burgdorferi, in its natural tick vector. Proc Natl Acad Sci U S A. 2005;102(19):6972–7. Epub 2005/04/30. pmid:15860579; PubMed Central PMCID: PMC1100799.
  56. 56. Rojas CM, Ham JH, Deng WL, Doyle JJ, Collmer A. HecA, a member of a class of adhesins produced by diverse pathogenic bacteria, contributes to the attachment, aggregation, epidermal cell killing, and virulence phenotypes of Erwinia chrysanthemi EC16 on Nicotiana clevelandii seedlings. Proc Natl Acad Sci U S A. 2002;99(20):13142–7. WOS:000178391700116. pmid:12271135
  57. 57. Miller WG, Lindow SE. An improved GFP cloning cassette designed for prokaryotic transcriptional fusions. Gene. 1997;191(2):149–53. WOS:A1997XG69400004. pmid:9218713
  58. 58. Lescot M, Audic S, Robert C, Nguyen TT, Blanc G, Cutler SJ, et al. The genome of Borrelia recurrentis, the agent of deadly louse-borne relapsing fever, is a degraded subset of tick-borne Borrelia duttonii. PLoS Genet. 2008;4(9):e1000185. Epub 2008/09/13. pmid:18787695; PubMed Central PMCID: PMC2525819.
  59. 59. Stewart PE, Thalken R, Bono JL, Rosa P. Isolation of a circular plasmid region sufficient for autonomous replication and transformation of infectious Borrelia burgdorferi. Mol Microbiol. 2001;39(3):714–21. Epub 2001/02/13. pmid:11169111.
  60. 60. Sartakova ML, Dobrikova EY, Terekhova DA, Devis R, Bugrysheva JV, Morozova OV, et al. Novel antibiotic-resistance markers in pGK12-derived vectors for Borrelia burgdorferi. Gene. 2003;303:131–7. Epub 2003/02/01. pmid:12559574.
  61. 61. Drecktrah D, Lybecker M, Popitsch N, Rescheneder P, Hall LS, Samuels DS. The Borrelia burgdorferi RelA/SpoT Homolog and Stringent Response Regulate Survival in the Tick Vector and Global Gene Expression during Starvation. PLoS Pathog. 2015;11(9). ARTN e1005160 WOS:000362269800032. pmid:26371761
  62. 62. Jorgenson MA, Bryant JC. A genetic screen to identify factors affected by undecaprenyl phosphate recycling uncovers novel connections to morphogenesis inEscherichia coli. Mol Microbiol. 2021;115(2):191–207. WOS:000578613600001. pmid:32979869
  63. 63. Boyle WK, Wilder HK, Lawrence AM, Lopez JE. Transmission dynamics of Borrelia turicatae from the arthropod vector. PLoS Negl Trop Dis. 2014;8(4):e2767. pmid:24699275; PubMed Central PMCID: PMC3974661.
  64. 64. McCoy BN, Raffel SJ, Lopez JE, Schwan TG. Bloodmeal size and spirochete acquisition of Ornithodoros hermsi (Acari: Argasidae) during feeding. J Med Entomol. 2010;47(6):1164–72. Epub 2010/12/24. pmid:21175068; PubMed Central PMCID: PMC3071302.
  65. 65. Guyard C, Raffel SJ, Schrumpf ME, Dahlstrom E, Sturdevant D, Ricklefs SM, et al. Periplasmic flagellar export apparatus protein, FliH, is involved in post-transcriptional regulation of FlaB, motility and virulence of the relapsing fever spirochete Borrelia hermsii. PLoS One. 2013;8(8):e72550. Epub 2013/09/07. pmid:24009690; PubMed Central PMCID: PMC3757020.
  66. 66. Blevins JS, Hagman KE, Norgard MV. Assessment of decorin-binding protein A to the infectivity of Borrelia burgdorferi in the murine models of needle and tick infection. BMC Microbiol. 2008;8:82. Epub 2008/05/30. pmid:18507835; PubMed Central PMCID: PMC2430964.
  67. 67. Stewart PE, Byram R, Grimm D, Tilly K, Rosa PA. The plasmids of Borrelia burgdorferi: essential genetic elements of a pathogen. Plasmid. 2005;53(1):1–13. WOS:000226314500001. pmid:15631949
  68. 68. Hinnebusch J, Barbour AG. Linear-Plasmid and Circular-Plasmid Copy Numbers in Borrelia-Burgdorferi. J Bacteriol. 1992;174(16):5251–7. WOS:A1992JH97900011.
  69. 69. Kitten T, Barbour AG. The Relapsing Fever Agent Borrelia-Hermsii Has Multiple Copies of Its Chromosome and Linear Plasmids. Genetics. 1992;132(2):311–24. WOS:A1992JQ14600004. pmid:1427031
  70. 70. Casjens S, Huang WM. Linear Chromosomal Physical and Genetic-Map of Borrelia-Burgdorferi, the Lyme-Disease Agent. Mol Microbiol. 1993;8(5):967–80. WOS:A1993LF03600017. pmid:8102774
  71. 71. Grimm D, Eggers CH, Caimano MJ, Tilly K, Stewart PE, Elias AF, et al. Experimental assessment of the roles of linear plasmids lp25 and lp28-1 of Borrelia burgdorferi throughout the infectious cycle. Infect Immun. 2004;72(10):5938–46. WOS:000224134000048. pmid:15385497
  72. 72. Jewett MW, Lawrence K, Bestor AC, Tilly K, Grimm D, Shaw P, et al. The critical role of the linear plasmid lp36 in the infectious cycle of Borrelia burgdorferi. Mol Microbiol. 2007;64(5):1358–74. WOS:000247175600016. pmid:17542926
  73. 73. Dulebohn DP, Bestor A, Rego ROM, Stewart PE, Rosa PA. Borrelia burgdorferi Linear Plasmid 38 Is Dispensable for Completion of the Mouse-Tick Infectious Cycle. Infect Immun. 2011;79(9):3510–7. WOS:000293891000004. pmid:21708994
  74. 74. Samuels DS, Drecktrah D, Hall LS. Genetic Transformation and Complementation. Methods Mol Biol. 2018;1690:183–200. pmid:29032546; PubMed Central PMCID: PMC5806694.
  75. 75. Hyde JA, Weening EH, Skare JT. Genetic transformation of Borrelia burgdorferi. Curr Protoc Microbiol. 2011;Chapter 12:Unit 12C 4. Epub 2011/03/15. pmid:21400675; PubMed Central PMCID: PMC3561735.
  76. 76. Li X, Pal U, Ramamoorthi N, Liu X, Desrosiers DC, Eggers CH, et al. The Lyme disease agent Borrelia burgdorferi requires BB0690, a Dps homologue, to persist within ticks. Mol Microbiol. 2007;63(3):694–710. Epub 2006/12/22. pmid:17181780.
  77. 77. Skare JT, Mirzabekov TA, Shang ES, Blanco DR, ErdjumentBromage H, Bunikis J, et al. The Oms66 (p66) protein is a Borrelia burgdorferi porin. Infect Immun. 1997;65(9):3654–61. WOS:A1997XT42000022.
  78. 78. Defoe G, Coburn J. Delineation of Borrelia burgdorferi p66 sequences required for integrin alpha(IIb)beta(3) recognition. Infect Immun. 2001;69(5):3455–9. WOS:000168158400088. pmid:11292775
  79. 79. Coburn J, Cugini C. Targeted mutation of the outer membrane protein P66 disrupts attachment of the Lyme disease agent, Borrelia burgdorferi, to integrin alpha(v)beta(3). Proc Natl Acad Sci U S A. 2003;100(12):7301–6. WOS:000183493500073. pmid:12748384
  80. 80. Coburn J, Chege W, Magoun L, Bodary SC, Leong JM. Characterization of a candidate Borrelia burgdorferi beta(3)-chain integrin ligand identified using a phage display library. Mol Microbiol. 1999;34(5):926–40. WOS:000084433900006. pmid:10594819
  81. 81. Antonara S, Chafel RM, LaFrance M, Coburn J. Borrelia burgdorferi adhesins identified using in vivo phage display. Mol Microbiol. 2007;66(1):262–76. WOS:000249927100019. pmid:17784908
  82. 82. Pinne M, Thein M, Denker K, Benz R, Coburn J, Bergstrom S. Elimination of channel-forming activity by insertional inactivation of the p66 gene in Borrelia burgdorferi. FEMS Microbiol Lett. 2007;266(2):241–9. WOS:000242785200017. pmid:17233736
  83. 83. Barcena-Uribarri I, Thein M, Sacher A, Bunikis I, Bonde M, Bergstrom S, et al. P66 porins are present in both Lyme disease and relapsing fever spirochetes: A comparison of the biophysical properties of P66 porins from six Borrelia species. Bba-Biomembranes. 2010;1798(6):1197–203. WOS:000278321200021. pmid:20188698
  84. 84. Caine JA, Coburn J. A Short-Term Borrelia burgdorferi Infection Model Identifies Tissue Tropisms and Bloodstream Survival Conferred by Adhesion Proteins. Infect Immun. 2015;83(8):3184–94. WOS:000357618300018. pmid:26015482
  85. 85. Kumar D, Ristow LC, Shi MQ, Mukherjee P, Caine JA, Lee WY, et al. Intravital Imaging of Vascular Transmigration by the Lyme Spirochete: Requirement for the Integrin Binding Residues of the B. burgdorferi P66 Protein. PLoS Pathog. 2015;11(12). ARTN e1005333 WOS:000368332800045. pmid:26684456
  86. 86. Frank KL, Bundle SF, Kresge ME, Eggers CH, Samuels DS. aadA confers streptomycin resistance in Borrelia burgdorferi. J Bacteriol. 2003;185(22):6723–7. pmid:14594849; PubMed Central PMCID: PMC262111.
  87. 87. Schwan TG, Battisti JM, Porcella SF, Raffel SJ, Schrumpf ME, Fischer ER, et al. Glycerol-3-phosphate acquisition in spirochetes: distribution and biological activity of glycerophosphodiester phosphodiesterase (GlpQ) among Borrelia species. J Bacteriol. 2003;185(4):1346–56. Epub 2003/02/04. pmid:12562805; PubMed Central PMCID: PMC142843.
  88. 88. Barbour A, Guo BP. Pathogenesis of relapsing fever. In: Radolf J, Samuels DS, editors. Borrelia: molecular biology, host interaction, and pathogenesis. Norfolk: Caister Academic Press; 2010. p. 333–58.
  89. 89. Eggers CH, Caimano MJ, Clawson ML, Miller WG, Samuels DS, Radolf JD. Identification of loci critical for replication and compatibility of a Borrelia burgdorferi cp32 plasmid and use of a cp32-based shuttle vector for the expression of fluorescent reporters in the lyme disease spirochaete. Mol Microbiol. 2002;43(2):281–95. pmid:11985709.
  90. 90. Tilly K, Checroun C, Rosa PA. Requirements for Borrelia burgdorferi plasmid maintenance. Plasmid. 2012;68(1):1–12. Epub 20120124. pmid:22289894; PubMed Central PMCID: PMC3367046.
  91. 91. Moriarty TJ, Norman MU, Colarusso P, Bankhead T, Kubes P, Chaconas G. Real-time high resolution 3D imaging of the lyme disease spirochete adhering to and escaping from the vasculature of a living host. PLoS Pathog. 2008;4(6):e1000090. Epub 20080620. pmid:18566656; PubMed Central PMCID: PMC2408724.
  92. 92. Miller JC, von Lackum K, Woodman ME, Stevenson B. Detection of Borrelia burgdorferi gene expression during mammalian infection using transcriptional fusions that produce green fluorescent protein. Microb Pathog. 2006;41(1):43–7. Epub 20060524. pmid:16723206.
  93. 93. Dunham-Ems SM, Caimano MJ, Pal U, Wolgemuth CW, Eggers CH, Balic A, et al. Live imaging reveals a biphasic mode of dissemination of Borrelia burgdorferi within ticks. J Clin Invest. 2009;119(12):3652–65. Epub 20091116. pmid:19920352; PubMed Central PMCID: PMC2786795.
  94. 94. Filatov S, Dycka F, Sterba J, Rego ROM. A simple non-invasive method to collect soft tick saliva reveals differences in Ornithodoros moubata saliva composition between ticks infected and uninfected with Borrelia duttonii spirochetes. Front Cell Infect Microbiol. 2023;13:1112952. Epub 20230120. pmid:36743301; PubMed Central PMCID: PMC9895398.
  95. 95. Bono JL, Elias AF, Kupko JJ, 3rd, Stevenson B, Tilly K, Rosa P. Efficient targeted mutagenesis in Borrelia burgdorferi. J Bacteriol. 2000;182(9):2445–52. pmid:10762244; PubMed Central PMCID: PMC111306.
  96. 96. Elias AF, Bono JL, Kupko JJ, 3rd, Stewart PE, Krum JG, Rosa PA. New antibiotic resistance cassettes suitable for genetic studies in Borrelia burgdorferi. J Mol Microbiol Biotechnol. 2003;6(1):29–40. pmid:14593251.
  97. 97. Sartakova M, Dobrikova E, Cabello FC. Development of an extrachromosomal cloning vector system for use in Borrelia burgdorferi. Proc Natl Acad Sci U S A. 2000;97(9):4850–5. pmid:10781091; PubMed Central PMCID: PMC18321.
  98. 98. Takacs CN, Kloos ZA, Scott M, Rosa PA, Jacobs-Wagner C. Fluorescent Proteins, Promoters, and Selectable Markers for Applications in the Lyme Disease Spirochete Borrelia burgdorferi. Appl Environ Microbiol. 2018;84(24). Epub 20181130. pmid:30315081; PubMed Central PMCID: PMC6275353.
  99. 99. Blevins JS, Revel AT, Smith AH, Bachlani GN, Norgard MV. Adaptation of a luciferase gene reporter and lac expression system to Borrelia burgdorferi. Appl Environ Microbiol. 2007;73(5):1501–13. Epub 2007/01/16. pmid:17220265; PubMed Central PMCID: PMC1828772.
  100. 100. Sohaskey CD, Arnold C, Barbour AG. Analysis of promoters in Borrelia burgdorferi by use of a transiently expressed reporter gene. J Bacteriol. 1997;179(21):6837–42. pmid:9352937; PubMed Central PMCID: PMC179616.
  101. 101. Alverson J, Bundle SF, Sohaskey CD, Lybecker MC, Samuels DS. Transcriptional regulation of the ospAB and ospC promoters from Borrelia burgdorferi. Mol Microbiol. 2003;48(6):1665–77. pmid:12791146.
  102. 102. Hayes BM, Jewett MW, Rosa PA. lacZ reporter system for use in Borrelia burgdorferi. Appl Environ Microbiol. 2010;76(22):7407–12. Epub 20100917. pmid:20851957; PubMed Central PMCID: PMC2976203.
  103. 103. Carroll JA, Stewart PE, Rosa P, Elias AF, Garon CF. An enhanced GFP reporter system to monitor gene expression in Borrelia burgdorferi. Microbiology (Reading). 2003;149(Pt 7):1819–28. pmid:12855733.
  104. 104. Schulze RJ, Zuckert WR. Borrelia burgdorferi lipoproteins are secreted to the outer surface by default. Mol Microbiol. 2006;59(5):1473–84. pmid:16468989.
  105. 105. Lee WY, Moriarty TJ, Wong CH, Zhou H, Strieter RM, van Rooijen N, et al. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol. 2010;11(4):295–302. Epub 20100314. pmid:20228796; PubMed Central PMCID: PMC5114121.
  106. 106. Lawrenz MB, Kawabata H, Purser JE, Norris SJ. Decreased electroporation efficiency in Borrelia burgdorferi containing linear plasmids lp25 and lp56: impact on transformation of infectious B. burgdorferi. Infect Immun. 2002;70(9):4798–804. pmid:12183522; PubMed Central PMCID: PMC128261.
  107. 107. Kawabata H, Norris SJ, Watanabe H. BBE02 disruption mutants of Borrelia burgdorferi B31 have a highly transformable, infectious phenotype. Infect Immun. 2004;72(12):7147–54. pmid:15557639; PubMed Central PMCID: PMC529111.
  108. 108. Chen Q, Fischer JR, Benoit VM, Dufour NP, Youderian P, Leong JM. In vitro CpG methylation increases the transformation efficiency of Borrelia burgdorferi strains harboring the endogenous linear plasmid lp56. J Bacteriol. 2008;190(24):7885–91. Epub 20081010. pmid:18849429; PubMed Central PMCID: PMC2593207.
  109. 109. Rego RO, Bestor A, Rosa PA. Defining the plasmid-borne restriction-modification systems of the Lyme disease spirochete Borrelia burgdorferi. J Bacteriol. 2011;193(5):1161–71. Epub 20101230. pmid:21193609; PubMed Central PMCID: PMC3067601.
  110. 110. Chung CT, Niemela SL, Miller RH. One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. Proc Natl Acad Sci U S A. 1989;86(7):2172–5. pmid:2648393; PubMed Central PMCID: PMC286873.
  111. 111. Elias AF, Stewart PE, Grimm D, Caimano MJ, Eggers CH, Tilly K, et al. Clonal polymorphism of Borrelia burgdorferi strain B31 MI: implications for mutagenesis in an infectious strain background. Infect Immun. 2002;70(4):2139–50. pmid:11895980; PubMed Central PMCID: PMC127854.